↓ Skip to main content

American Association for Cancer Research

Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

Overview of attention for article published in Molecular Cancer Therapeutics, June 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

patent
21 patents

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
28 Mendeley
Title
Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases
Published in
Molecular Cancer Therapeutics, June 2010
DOI 10.1158/1535-7163.mct-10-0203
Pubmed ID
Authors

Daniel A. Vallera, Seunguk Oh, Hua Chen, Yanqun Shu, Arthur E. Frankel

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 4%
India 1 4%
Unknown 26 93%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 21%
Researcher 5 18%
Student > Ph. D. Student 4 14%
Other 3 11%
Student > Doctoral Student 2 7%
Other 5 18%
Unknown 3 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 10 36%
Biochemistry, Genetics and Molecular Biology 4 14%
Medicine and Dentistry 4 14%
Engineering 2 7%
Chemistry 1 4%
Other 1 4%
Unknown 6 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2024.
All research outputs
#3,320,137
of 23,053,169 outputs
Outputs from Molecular Cancer Therapeutics
#512
of 3,876 outputs
Outputs of similar age
#13,003
of 96,834 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#9
of 56 outputs
Altmetric has tracked 23,053,169 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,876 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 96,834 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.